NSE filing, NSE: ICICIPRULI. Summary written from the filing by ALFA Finder's alert engine.
ICICI Prudential Life Insurance Company Ltd: key numbers
- Share price
- ₹412.00
- Market cap
- ₹59,789 Cr
- Revenue (annual)
- ₹63,467 Cr
- Net profit (annual)
- ₹1,600 Cr
- P/E (TTM)
- 34.0×Sector 19.7×
- Promoter holding
- 74.70%+1.97% QoQ
- FII holding
- 9.26%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from ICICI Prudential Life Insurance Company Ltd
All →ICICI Life Insurance Employee Stock Options
ICICI Prudential Life Insurance allotted 2,697 equity shares under its ESUS 2023 scheme on October 21, 2026. No transaction value is disclosed for this ESOP allotment.
ICICI Life Insurance Legal & Regulatory
ICICI Life Insurance received an Income Tax rectification order for Assessment Year 2023, resulting in a total financial impact of ₹591.42 Crore.
- Value
- ₹591.4 Cr
- From
- Assistant Commissioner of Income Tax, Mumbai
ICICI Life Insurance Legal & Regulatory
ICICI Life Insurance received an income tax rectification order for Assessment Year 2023, resulting in a total incremental tax and interest demand of ₹230.19 Crore.
- Value
- ₹230.2 Cr
- From
- Income Tax Department
ICICI Life Insurance Legal & Regulatory
ICICI Life Insurance received an income tax rectification order for AY 2024, resulting in a reduced tax demand and adjusted interest impact of ₹278.90 Crore.
- Value
- ₹278.9 Cr
- From
- Assistant Commissioner of Income Tax
ICICI Life Insurance Legal & Regulatory
ICICI Life Insurance received an Income Tax rectification order for AY 2024, resulting in incremental interest of ₹ 40.96 Lakhs. The company has appealed the order.
- Value
- ₹0.41 Cr
ICICI Life Insurance Other Announcement
NSE has approved a change in the company's name to ICICI Life Insurance Limited and its trading symbol to ICICILIFE, effective October 23, 2026.
Other regulatory approval announcements
All →Shalby Regulatory Approval
Shalby Hospital, Jabalpur received CMHO permission to resume normal operations, including patient admissions, on its previously affected floor. The hospital has now fully resumed healthcare services.
Elantas Beck India Regulatory Approval
Elantas Beck India's GPCB permanently revoked the closure direction on its Ankleshwar plant. The facility can keep operating, subject to compliance conditions.
Kalyani Cast-Tech Regulatory Approval
Kalyani Cast-Tech received RDSO Stage-I concept design approval for its new container-carrying wagon under PWDA. Stage-II detailed design approval is still required, subject to dynamics simulation conditions.
Mukka Proteins Regulatory Approval
Mukka Proteins received a US FDA facility registration certificate, valid October 1, 2026 to December 31, 2027. The company says the registration supports its engagement with US customers and markets.
- Execution
- October 1, 2026 to December 31, 2027
Canara Bank Regulatory Approval
Canara Bank received RBI permission to exercise the call option on its Basel III AT1 bonds (ISIN INE476A08134) of Rs.1,500 Crore. The bank is now in process of exercising the call as per the issue terms.
- Value
- ₹1,500 Cr
Alembic Pharmaceuticals Regulatory Approval
Alembic Pharmaceuticals received USFDA final approval for Valganciclovir for Oral Solution, 50 mg/mL. This adds to its cumulative 247 USFDA ANDA approvals.